Ya know I forgot to check, thanks.

swampie: APT

Are U still holding the 100K shares U bought at that price!!!

Swamp you are an idiot and 2 weeks late to save 1/2 mill. lives with greater following!

Yes Swamp I heard all about it, Covid-19, wish I took it as serious as I do now!

Swamp ever hear of the new virus?

Swamp ever hear of Ebola?

Businessweek slaps FDA:

http://www.businessweek.com/articles/2013-12-23/fda-inaction-on-antibiotics-is-making-the-world-deadlier?campaign_id=yhoo

APT 2.04. building part ramping also.

CEL-SCI and NIAID Publish Data Showing That CEL-SCI's LEAPS Technology Halted Progression of Lethal Influenza in Three Different Influenza Virus Strains, Including a Drug-Resistant and a 2009 Pandemic Flu Strain

www.nasdaq.com/press-release/cel-sci-and-niaid-publish-data-showing-that-cel-scis-leaps-technology-halted-progression-of-lethal-influenza-in-three-different-influenza-virus-strains-including-a-drug-resistant-and-a-2009-pandemic-flu-strain-20130725-00446

27 dead H7N9 latest, 127 infected China.

BEIJING | Thu May 2, 2013 3:38am EDT

(Reuters) - A 55-year-old man in central China has died from a new strain of bird flu, bringing to 27 the number of deaths from the mysterious H7N9 virus, state news agency Xinhua said on Thursday.

The H7N9 virus, which has infected 127 people in China, is a threat to world health and should be taken seriously, scientists said on Wednesday.

The Geneva-based World Health Organization (WHO) has described it as "one of the most lethal" flu viruses but said there is as yet no evidence of human-to-human transmission of this virus.

The latest victim, a native of southeastern Jiangxi province surnamed Jiao, died in Hunan province, Xinhua said. The man sold braised pork and was diagnosed with the H7N9 virus on April 26, the Hunan Health Bureau said on its website.

A 69-year-old farmer, also from Hunan, was the latest person to be infected with the virus, state media said.

So far, 26 people have recovered after contracting the virus, according to Xinhua.

Chinese scientists have confirmed for the first time that the H7N9 strain has been transmitted to humans from chickens.

Last week a man in Taiwan became the first case of the flu outside mainland China. He caught the flu while traveling in China.

(Reporting by Sui-Lee Wee; Editing by Michael Perry)

China says new bird flu case found in northeast

BEIJING (Reuters) - A man in the northeastern Chinese province of Shandong has been infected by a new strain of bird flu, the first case found in the province, state news agency Xinhua said on Monday, bringing the total number of victims in China to 105.

H7N9 Outbreak Cases Double in Week

Check graphics at Bberg - don't know but this thing looks might strong!

Flu Experts Probe H7N9 Outbreak as Cases Double in a Week
http://www.bloomberg.com/news/2013-04-19/flu-experts-probe-h7n9-outbreak-as-cases-double-in-a-week.html

By Bloomberg News - Apr 19, 2013 2:51 AM ET .

Influenza specialists from around the world are converging on China to help authorities identify how people are catching the new H7N9 bird flu strain after the number of reported cases there doubled in the past week.

China recorded its 88th H7N9 infection yesterday. Seventeen of the cases have been fatal and “several” patients are in critical condition, according to the World Health Organization.

This photo taken on April 14, 2013 shows a man carrying a basket of newborn ducklings before he incinerates them in a stove at a duck farm in Zhangzhou, south China's Fujian province. Source: AFP via Getty Images
.
“That’s a fairly high mortality rate,” Michael O’Leary, the WHO’s China representative, told reporters in Beijing today. Less severe cases may have escaped detection, he said. “What we don’t know is the size of the iceberg under this tip.”

China’s H7N9 bird flu outbreak has a puzzling feature: most of those getting sick and dying from the pneumonia-causing virus are elderly men, data compiled by Bloomberg show. In contrast, earlier this week, a 4-year-old boy in Beijing became the first reported case of an infection without illness.

The Geneva-based WHO started a joint assessment panel with Chinese health authorities comprising 15 foreign and Chinese specialists that will visit hospitals in the affected cities, O’Leary said. The panel “will mainly investigate the sources of the virus” and will provide recommendations and a risk control plan at a later time, he said.

Flu Team

Nancy Cox, director of the flu division at the U.S. Centers for Disease Control and Prevention in Atlanta; Anne Kelso, director of a WHO flu research center in Melbourne, Australia; Malik Peiris, chairman of virology at the University of Hong Kong; and Angus Nicoll, head of the Stockholm-based European Centre for Disease Prevention and Control’s flu program, were to arrive in China earlier this week, according to two people familiar with the matter.

An “important area of suspicion” about human exposure to the H7N9 virus is in markets where live butchering of chickens is carried out, said Feng Zijian, director of public health emergency at the Chinese Center for Disease Control and Prevention.

Fowl in these markets are usually defeathered by being plunged into vats of spinning boiling water, which could create aerosols that are inhaled by people passing by, Feng said, according to a transcript posted on the agency’s website yesterday.

While it isn’t possible to determine if sustained person- to-person transmission of the H7N9 flu strain is possible, “if the virus is to change, there might be risks,” O’Leary said at today’s briefing.

A new flu strain against which nobody has natural immunity could touch off a pandemic if it’s capable of spreading easily and efficiently among people, such as what happened in 2009, after a novel strain of swine flu, called H1N1, emerged in Mexico.

“We never know when the pandemic influenza will arrive and there might be false alarms, but we are still in early investigations, so there’s no reason to panic or be overly concerned,” O’Leary said.

To contact Bloomberg News staff for this story: Daryl Loo in Beijing at dloo7@bloomberg.net; Sarah Chen in Beijing at schen514@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

APT 1.61 started .

NANM should be in play soon with BCRX and SVA running.

Right, and couple others

Short airlines?

http://www.reuters.com/article/2013/04/05/us-birdflu-china-idUSBRE93201G20130405?feedType=RSS&feedName=healthNews

The virus has been shared with World Health Organization (WHO) collaborating centers in Atlanta, Beijing, London, Melbourne and Tokyo, and these groups are analyzing samples to identify the best candidate to be used for the manufacture of vaccine - if it becomes necessary.

Any decision to mass-produce vaccines against H7N9 flu will not be taken lightly, since it will mean sacrificing production of seasonal shots.

That could mean shortages of vaccine against the normal seasonal flu which, while not serious for most people, still costs thousands of lives.

Sanofi Pasteur, the world's largest flu vaccine manufacturer, said it was in continuous contact with the WHO through the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), but it was too soon to know the significance of the Chinese cases.

Other leading flu vaccine makers include GlaxoSmithKline and Novartis

Preliminary test results suggest the new flu strain responds to treatment with Roche's Tamiflu and GSK's Relenza, according to the WHO.

OK 6 cases and they killed 20,000 birds..........stocks must be bought to matched this malady..........APT?

First two China deaths H7N9 bird flu

Two People In China Die From Bird Flu

by Agence France Presse on Mar 31, 2013, 10:13 AM
Two people in China have died after being infected with H7N9 avian influenza -- a sub-type that had not previously been transmitted to humans -- the government said Sunday.
An 87-year-old man in Shanghai fell ill on February 19 and died on March 4, while a man aged 27 in the city got sick on February 27 and died on March 10, the National Health and Family Planning Commission said on its website.
A 35-year-old woman in the eastern province of Anhui became ill on March 9 and is in critical condition, it said.
All three initially suffered fever and coughs but later developed severe pneumonia and problems with breathing, according to the announcement.
The three cases were confirmed Saturday to be infections with the H7N9 sub-strain after the Chinese Center for Disease Control and Preservation had separated it from body samples the day before, the commission said.
The route of infection remained unknown although nothing unusual was detected among 88 people close to the victims, the commission said.
The H7N9 strain had not been transmitted to humans before, it added.
In a separate release, the commission said there are currently no vaccines against H7N9.
It also explained that the delay in announcing the results was because it took time to determine the cause of the illnesses.
The World Health Organisation (WHO), in an emailed statement to AFP, said there was no evidence of human-to-human transmission in the three reported cases.
It also said transmission to humans "would appear to be inefficient, leading us to believe that the risk to public health is low".
But the WHO said it was continuing closely to monitor the situation.
China is considered one of the nations most at risk from bird flu because it has the world's biggest poultry population and many chickens in rural areas are kept close to humans.
It has in the past been accused of covering up the extent of bird flu outbreaks, exacerbating fears when new cases are reported.
The WHO says more than 360 confirmed human deaths from the H5N1 strain of avian influenza have been reported to it globally from 2003 until March 12 this year.
It says other sub-types have infected humans, including H7N7 and H9N2, and some of these infections led to deaths.
Copyright (2013) AFP. All rights reserved.

http://seekingalpha.com/instablog/224349-allan-harris/991091-got-flu

L vus Monday, August 27, 2012 7:53:40 PM
Re: None Post # of 62368

Cox has followed up with another article:

Fortunately, there's plenty of news for me to share that has importance far past these next few days. In fact, the two items in the headline will have obvious and measurable impacts on national and international health and longevity statistics. These impacts are also the basis for enormous financial value.

Some cost estimates of normal seasonal influenza in the U.S., both direct and indirect, range as high as $150 billion annually. If it's only half that, which is clearly too low, it is still a significant drag on economic growth and the good things that come with it.The economic impact of a true pandemic in America would be at least twice that. The cost in Europe would be about twice the American costs. Internationally, the total impact of an influenza pandemic would easily move into the trillions of dollars.

Let's look at a normal year, however. Typically, about 35 million people get the flu yearly in the United States. This number applies even in those years when flu vaccines have hit their mark and are capable of preventing influenza. Vaccination will never be widely adopted.

The cost of a course of Tamiflu, which is largely ineffective, runs about $80. When we believed that the NanoViricides flu drug would have to be delivered via injection, it was very difficult to project its use. Now, however, we know that these polymer/ligand constructs can survive the stomach and be delivered orally. For that reason, I think that it is entirely reasonable to assume that 30 million people would take a treatment for a dangerous flu that would end symptoms in just an hour or two -- every year. Insurance companies would pay for the vast majority of uses.

So $100 times 30 million uses is $3 billion a year. Double that for the European market and double it again for the world and you have potential sales easily exceeding $10 billion annually. Remember, this is an extremely inexpensive drug to manufacture when scaled up, so most of that revenue would fall into the profits column. When a pandemic hits, you would double sales… at least.

The reason I say "at least” is that an orally deliverable drug would work for flu prophylaxis, or prevention. Remember, nanoviricides are big molecules compared with small molecule proteins. They are not metabolized and persist in the blood system for an extremely long time, perhaps months. This means that many people who are not at high risk for the flu would probably take the drug as soon as a pandemic hit anyway.

Interestingly, it would not prevent infection by the virus. This is a feature, however, not a bug. When the virus is contracted by someone with nanoviricides in their system, very low-level infection occurs in at least a few lung cells. This is all the immune system needs to create a lasting immunity. NanoViricides' flu drug would, therefore, facilitate a kind of natural inoculation, allowing huge populations to develop immunities to otherwise life-threatening viruses without ever getting sick.

If I could provide a soundtrack with this letter, you'd hear a chorus of angels singing now. Seriously, this drug has the potential to change world history and accelerate global progress measurably. That, however, is only the beginning.

Now that we know that nanoviricides for influenza can be delivered orally, the odds are that an HIV ligand that can survive will also be identified. That would be the end of AIDS as we know it, which would lift Africa out of the dark ages. Global domestic product would be kicked up a notch, which would benefit everybody by increasing trade and wealth internationally.

Also likely targets for oral drugs are herpes, Ebola, dengue, etc. In fact, all viruses now are threatened by oral drugs, even more-obscure viruses like human papillomavirus and the deadly hantaviruses. I hear angels singing again, accompanied by the sound of cash register bells.

Allow me to explain the ligand comment I made earlier. Some of you may notice that the press release announcing the oral drug put mouse survival at 347 hours, or 14.5 days. Previous NanoViricides tests of an influenza nanoviricide, you may recall, resulted in survival past 500 hours, or 20 days, which is long enough for the mice to develop immunities and beat the illness.

The reason that results were different is that the ligand on that optimized injectable version of the drug did not survive in the gut when tested as an oral drug. Fortunately, another ligand was used for the current animal test that easily survives. Moreover, we also know two things that make the 347-hour drug just as effective as the injectable ligand.

First, prior toxicity tests show remarkable tolerance for these nanoviricides, so doses can be upped to increase effectiveness. Second, we know that effectiveness is, in fact, dose dependent. This means that a slightly larger dose of the new ligand would almost certainly take the mice out past the 500-hour mark. Similarly, a human drug could be formulated that would provide a complete influenza cure using the orally deliverable ligand.

I asked Dr. Anil Diwan if that meant that he would take the prior optimized version through the regulatory process for an injectable hospital drug while taking the ligand that survives in the stomach through the process for an oral drug. He responded by saying, that would be logical, wouldn't it, but we're dealing with regulators and we'll just have to see what they want.

It may be that it will be easier to get the stomach-safe ligand approved both for the injectable and oral drugs. We don't know yet. Regulatory approval, of course, is the last hurdle before this world-changing technology comes to market. The company continues to develop its own manufacturing facilities in Connecticut. Even that hurdle could be bypassed by going to a contract manufacturer if the next pandemic hits before the company is ready to manufacture on a mass scale

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78977973

This oral flu formulation is a big plus for Nanoviricides. As I've said before if you are not willing to wait forever and take a huge chance on bio drugs then you should avoid them.

NanoViricides Reports that Oral Administration of FluCide(R) Anti-Influenza Drug Candidates Caused Lung Viral Load Decrease Comparable to IV Administration and Far Superior to Oseltamivir, in a Highly Lethal Animal Model
7:00a ET August 27, 2012 (Business Wire) NanoViricides, Inc. (OTCBB: NNVC) (the "Company") announced today that anti-influenza drug candidates under its FluCide(TM) program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load. Two different anti-influenza drug candidates were tested in Oral vs. IV comparison, and both of them showed similar results that indicated strong oral effectiveness. The results clearly demonstrated that oral administration of both of these FluCide drug candidates resulted in substantially superior animal protection compared to oseltamivir (Tamiflu(R)), a standard of care for influenza at present. The studies involved the same highly lethal animal model the Company has continued to use for its influenza drug development program.

One of the FluCide drug candidates, when administered orally, resulted in 1.30 log reduction (or 20X reduction) in lung viral load and matched the viral load reduction on the same drug candidate given as an IV injection. Another drug candidate resulted in 1.23 log viral load reduction when given orally and 1.31 log viral load reduction when given as an injectable. In contrast, oseltamivir (Tamiflu(R), given orally at 40mg/kg/d) resulted in only 0.6 log viral load reduction (or only 4X reduction) compared to negative controls. These were the results of lung viral load measured at 108 hours post-infection (hpi). Further, at 180 hpi, the lung viral load remained controlled at about the same level as at 108 hpi with the nanoviricide(R) drug candidates. In contrast, lung viral load in the oseltamivir treated mice increased to the same level as the negative control (infected untreated) animals prior to their death and the oseltamivir group exhibited a survival of only 182±4 hours.

The number of lung plaques and plaque areas (resulting from the influenza virus infection) also were consistent with the data from the lung viral load, and were minimal in the case of the nanoviricide drug candidates whether given as IV or orally. Oseltamivir treatment did not protect the lungs of infected animals anywhere close to the protection afforded by the FluCide drug candidates.

These data clearly demonstrated that both oral and IV treatment with nanoviricide drug candidates protected the lungs of the mice infected with influenza virus equally well. It is also clear that this lung protection was the result of the substantial decrease in the lung viral load. In addition, they show that FluCide drug candidates when given orally had substantial efficacy, almost matching the effectiveness of the injectable form given at 0.3X of the oral dosage level.

These data also clearly demonstrated that the FluCide drug candidates were substantially superior to oseltamivir or Tamiflu, the current standard of care for influenza infections.

The Company has previously said that the chemistries were modified in an attempt to make its drug candidates potentially available for oral administration. The Company had previously reported lung viral load reduction as high as 3 logs (1,000X) with its best injectable FluCide candidate in the same highly lethal animal model. The Company believes that oral administration is an important attribute and the trade-off in efficacy due to the change in chemistry is acceptable.

"We can easily increase the effectiveness of our drugs by increasing the oral dosage," said Anil R. Diwan, PhD, noting further that, " we have seen no adverse events in this study."

Tail-vein injections were given at 48 hr intervals starting at 24 hrs post-infection. Oral FluCide was given once daily. Oseltamivir was given twice daily (total 40mg/kg per day). The total quantity of FluCide drug given orally was 3.33 times that of the drug given as injectable, to adjust for expected reduction in the amount of drug going into circulation.

The Company is awaiting additional data from the studies and intends to release information as the data are analyzed and studied.

Nanoviricides, Inc. has been working on the development of an orally available nanoviricide for several years now. The essential chemistries were finally worked out during the CMC (Chemistry, Manufacturing, and Controls) studies for our current FluCide(TM) drug candidate. An initial feasibility study to determine whether a nanoviricide anti-influenza drug candidate would work when administered orally was undertaken perviously and had shown positive indications. The Company continued further development and has now completed a definitive animal model study to determine whether one of the FluCide anti-influenza drug candidates was effective when administered orally. The study was performed by KARD Scientific Inc. in the highly lethal influenza animal model as previously described.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE: NanoViricides, Inc.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com


http://ih.advfn.com/p.php?pid=nmona&article=53949922

Bird-Flu Research May Be Published by Journals, U.S. Says
By Alex Wayne - Apr 20, 2012 10:37 AM GMT-1000

The U.S. government said it will allow publication of research by scientists who re-engineered the avian influenza virus to make it more lethal.

The research is critical to understanding and detecting bird flu strains, Health and Human Services Secretary Kathleen Sebelius and Francis Collins, director of the National Institutes of Health, said today in a statement.

Publication has been on hold since December, when Sebelius’s agency asked the journals Science and Nature to censor some data in the interest of national security.

Groups led by the two scientists -- Yoshihiro Kawaoka of the University of Wisconsin and Ron Fouchier of Erasmus Medical Center in Rotterdam -- engineered the H1N1 virus to be more transmissible between ferrets, mammals whose response to the flu is most like humans. Science, which is holding the Fouchier paper, is waiting until after a meeting of Dutch regulators in The Hague next week before deciding when it will publish the work, Kathy Wren, a spokeswoman for the journal, said by phone.

“This information has clear value to national and international public health preparedness efforts and must be shared,” Collins said in the statement.

The U.S. National Science Advisory Board for Biosecurity recommended in March that Sebelius and Collins approve publication. A World Health Organization panel met in Geneva in February and recommended publication of the studies.

To contact the reporter on this story: Alex Wayne in Washington at awayne3@bloomberg.net
To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

http://ih.advfn.com/p.php?pid=nmona&article=51858091&symbol=NNVC

NNVC presents pre-IND to FDA for FluCide candidate:

http://ih.advfn.com/p.php?pid=nmona&article=50302111&symbol=NNVC

Not a "play" for me but buy and hold.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67040222

Haven't even looked at ages.

BCRX SVA NVAX NANM etc.

Anyone have any other Bird Flu plays?

Mutant Bird Flu Strain Spreading In Asia

http://www.huffingtonpost.com/2011/08/29/bird-flu-asia-mutant-strain-h5n1_n_940185.html?icid=maing-grid10%7Chtmlws-main-bb%7Cdl1%7Csec1_lnk2%7C90420

Biotech and the Unintended Consequences of Moore’s Law


Quote:
--------------------------------------------------------------------------------
Fighting the “Stupid Virus” Pandemic

The chasm between the actual state of the science and the public's perception of science puts more than money at risk. Lives are endangered by the inability of public institutions to deal with the new pace of scientific progress.

A prime example can be found in the anti-virus arena. We know another influenza pandemic will emerge in the next few years. Massive resources are therefore being spent to prepare for this inevitability. Scientists are trying now to predict which flu strains are likely to hit. Companies are preparing to manufacture enormous quantities of vaccines as quickly as possible.

Vaccinating for rapidly mutating viruses is, however, a fundamentally irrelevant technology. Unfortunately, few seem to know that there is a far cheaper and more effective solution to influenza.

This technology has come out of advances in nanotechnology and has been enabled by supercomputers. I'm not speaking theoretically, by the way. The solution for rapidly mutating viruses exists now. The company that developed it, however, has garnered only a fraction of the attention it deserves.

NanoViricides Inc. creates nanotech constructs made of submicroscopic polymers and biological ligands. They are called, not coincidentally, nanoviricides. The polymer portion of these constructs are approximately spherical virus traps. If you can think of a virus as a key that cracks the cellular safe, imagine ligands as the locks. A biologist would probably prefer “biological signaling molecules.”

Regardless, ligands that match specific virus families are identified using supercomputer simulations. When attached to the polymers and introduced into the blood stream, these nanoviricides are more attractive to viruses than actual cells. Viruses enter into the nanoviricides and are dismantled harmlessly.

If this technology sounds to you like something out of Isaac Asimov's Fantastic Voyage, you're not alone. When I first began writing about NanoViricides, the top Google search results were organized attacks on the company. A cottage industry existed that sold so-called reports that offered “the truth” about the company. Often, I was personally accused by those attacking NanoViricides of helping perpetrate a scam.

Fortunately, recent collaborations with world-renowned virus researchers has largely ended such attacks. Already, the company has demonstrated nanoviricides that lure and kill herpes, dengue and influenza viruses. In the last weeks, animal tests proved an effectiveness at killing influenza viruses that is orders of magnitude greater than Tamiflu.

All of the most infamous and scary strains of influenza were destroyed by NanoViricides' FluCide. Any future mutation of these viruses will also be destroyed. This technology, if it were approved and distributed widely, would allow us to stop worrying about influenza. At the first indication of the flu, a nanoviricide injection, skin patch or nasal spray would end flu symptoms within a few hours, no matter how lethal the virus is in nature.

Because nanoviricides operate in a biological/mechanical fashion, we don't need to worry that they will not work in humans. They work anywhere they are encountered by their target viruses. They have virtually no toxicity. They are cheap and have enormously long shelf lives. I would not hesitate to accept an injection right now. When the next pandemic inevitably arrives, I hope to do just that.

Nevertheless, I often read articles in the popular press about some new discovery that “will one day make nanotech medicine a reality.” On the contrary. It is a reality now, though we have not yet as a society understood and implemented this nanotechnology.

This is the unintended consequence of Moore's law. Science is advancing so fast that hundreds of thousands will probably die unnecessarily before we make the transition from influenza vaccines to nanoviricides. There is a very real war being fought right now between ignorance and science. Science will win but it would be nice if it won sooner than later.
--------------------------------------------------------------------------------



http://www.investorsinsight.com/blogs/john_mauldins_outside_the_box/archive/2011/06/13/biotech-and-the-unintended-consequences-of-moore-s-law.aspx

More FluCide news:

http://ih.advfn.com/p.php?pid=nmona&article=47204619&symbol=NNVC

NanoViricides Reports FluCide™ Drug Candidates Found to Offer Significant Protection Against Devastating Lung Lesions in Le...

Nanoviricides (OTCBB:NNVC)
Intraday Stock Chart
Today : Monday 4 April 2011
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

Four days post virus infection, animals treated with three of the optimized FluCide™ nanoviricide drug candidates exhibited greater than 95% reduction in the number of lung lesions as compared to the infected yet untreated control animals (p-values < 0.001). In contrast,animals treated with Oseltamivir (Tamiflu®, Roche) showed only a 50% reduction. In another significant finding, no increase in the number or size of the lung lesions was observed over the entire duration of the study in the FluCide™-treated animals. This was not the case for the Oseltamivir-treated animals. This demonstrated that treatment with FluCide drug candidates provided clear and strong protection against lung damage caused by the severe influenza infection.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of study was 21 days.

The Company had previously reported that the same three optimized FluCide™ nanoviricide drug candidates achieved significantly increased survival (20.2 to 22.2 days) as compared to animals treated with Oseltamivir (only 8.3 day survival). The lung histology (microscopic tissue examination) data show that the observed increase in survival was accompanied by a dramatic reduction in virus-induced lung inflammation and necrosis.

“Protection of the FluCide-treated animals against the development of influenza-specific lung inflammation and necrosis, together with the markedly extended survival clearly demonstrate the therapeutic potential of these FluCide nanoviricide drug candidates,” said Dr. Krishna Menon, KARD Scientific, adding, “Importantly, there were no drug-related side effects observed in the FluCide-treated animals.”

Pulmonary viral load studies, another important tool for evaluation of drug effectiveness, are currently in process. The results will be reported when they become available.

“These studies have clearly demonstrated that FluCide drug candidates are significantly superior to current therapies for influenza in animal models,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “Lung damage is a very important part of the pathology of influenza virus infection. Uncontrolled lung damage is associated with viral pneumonitis that, in severe cases of influenza, can lead to respiratory failure and refractory shock, the two most common causes of death. The world has seen such severe cases in the recent H1N1 pandemic, and continues to witness them with sporadic cases of H5N1 bird flu infections. We are very pleased with the finding that FluCide can protect animals against influenza viral lung damage.”

The Company is presenting its work at the 2nd Annual “Encouraging Development of Therapeutics for Neglected Diseases” Conference being held in Philadelphia, PA, today, April 4th. The Company has sponsored a luncheon presentation at this Conference. Anil R. Diwan, PhD, President of the Company, will be presenting the Company’s work on neglected diseases including Dengue, Rabies, Ebola, and Bird Flu (H5N1). The Company plans to include the late-breaking information discussed in this press release in the presentation.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.


http://ih.advfn.com/p.php?pid=nmona&article=47147694&symbol=NNVC

Newest NNVC FluCide results with tweaked dosage:

http://ih.advfn.com/p.php?pid=nmona&article=46951132&symbol=NNVC

NanoViricides, Inc. Reports Dramatically Extended Survival for FluCide(TM) Treated Animals in an Influenza Lethality Study
7:00a ET November 1, 2010 (Business Wire)
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported today that its FluCide(TM) drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu(R) treated animals.

Animals treated with the best of the optimized FluCide nanoviricide drug candidates survived greater than twice as long (18.1 days) as opposed to the animals treated with Tamiflu (only 7.8 days). In a previous study, the Company had reported that animals treated with the then best anti-influenza nanoviricides survived for as long as 13.9 days in the same animal model.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with FluCide candidates as well as Tamiflu(R) (Roche) commenced 24 hours after the first viral infection.

Additional clinically important parameters including viral load, and lung histopathology are being analyzed to confirm the therapeutic potential of the FluCide drug candidates. The results of these investigations will be reported as they become available.

"We are extremely happy with the substantially improved performance achieved in our optimization efforts," said Randall Barton, PhD, Chief Scientific Officer of the Company, adding, "An increase in dosage is now likely to lead to total survival even in this completely lethal virus challenge model."

"Our Influenza Program is progressing satisfactorily towards a pre-IND submission to the FDA in the near future," said Eugene Seymour, MD, MPH, CEO of the Company.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE: NanoViricides, Inc.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

H1N1 virus suspected in Calif. teachers death.

http://www.appeal-democrat.com/news/school-100192-district-purdie.html

New strain of swineflu:

http://af.reuters.com/article/worldNews/idAFTRE69K3WC20101021

You should make this a bioterror board as well since much of the government policy and funding, as well as busines investment and research, also meshes the two.

For instance, AEMD:

Aethlon Medical Reestablishes Biodefense Programs
PRNewswire

SAN DIEGO, Sept. 21, 2010 -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier® within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats. The Aethlon Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. Based on studies conducted by government and non-government research organizations, Aethlon believes the Hemopurifier® represents the most advanced and perhaps the only true broad-spectrum countermeasure against viral threats most likely to be weaponized against civilian and military populations.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Therapeutics able to target multiple bioterror threats have become a focal point of the U.S. Health and Human Services Department (HHS) and dual-use therapies such as the Hemopurifier®, that also have commercial applications against established disease conditions such as hepatitis-C virus (HCV) and cancer, are no longer precluded from consideration to be supported by government programs.

"Revamped government policies expand the opportunity for our Hemopurifier® in the United States and improve our potential access to non-dilutive capital resources, which are not capped by the public market value of our organization," stated Aethlon Chairman and CEO, Jim Joyce. "We now plan to update an investigational device exemption (IDE) already submitted to the FDA, which if approved, would allow us to collect further clinical data that potentially could contribute to other infectious disease and cancer studies we hope to initiate in the United States."

The IDE previously submitted to the FDA by Aethlon specifies the Hemopurifier® as a medical device for the single-use removal of bioterror related viruses from circulation. As efficacy studies against such pathogens cannot be conducted in humans, the demonstration of treatment safety represents the primary treatment challenge in humans. While efficacy studies against such threats may not be permissible, Aethlon has demonstrated significant viral load reductions in HIV and HCV infected individuals. In vitro studies have verified that the Hemopurifier® has broad-spectrum capabilities against both bioterror and emerging pandemic threats. These studies confirmed the ability of the Hemopurifier® to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

The landscape to encourage countermeasure development is rapidly improving. Last month, the Obama administration announced it would seek to improve government efforts to spur development of countermeasures for potential biological-weapon agents and HHS declared that programs intended to prepare the country for biological weapons attacks would be overhauled with a focus toward decreasing the length of time it takes to produce new medical countermeasures, and that new institutes would be established to collaborate with small firms on the production of new treatments. Additionally, funding will be directed to the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) to turn scientific breakthroughs into medical countermeasures. From a regulatory perspective, the FDA has indicated that it will take steps to eliminate obstacles that could slow the pace of the countermeasure review process.

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.


The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

That was deep.

I wonder why birds just hang out on power lines? Just stand and hang out. Flying must be cool. Just swoop and glide in the air and not have to worry about the cops stopping you for the red light you ignored.

We need to add Bed Bugs to our list!

,,,,,,,I resign...my hard work has been futile. Send shelly a mod request she's aware.

Millions of birds set to fly into Gulf oil mess.

Millions of birds on their fall migration will arrive in the Gulf soon, either to roost for the winter or for stopovers, and when they do the spill's casualty count could jump dramatically.

BP spill sets a somber record as Gulf's biggest

http://www.msnbc.msn.com/id/38037033/ns/us_news-environment/

Hopefully a cure for viral infections is not far away:

http://breakthroughtechnologyalert.agorafinancial.com/2010/05/24/wealth-revelations-2010-a-lifetime-of-wealth-from-four-miracle-research-companies/

You said "The swine flu is not dead, so I think those who think it was all done to hype it for a profit are just shy of reality.

Sure someone makes a dollar, but it was justified. "

"The swine flu is not dead" - This is correct.

"so I think those who think it was all done to hype it for a profit are just shy of reality" - Prove otherwise. Test after test proved that that great majority of the people who were said to have the swine flu actually never had it: http://coto2.wordpress.com/2009/10/29/cdc-and-swine-flu-deception-cbs-news-reveals-numbers-greatly-exaggerated/";

When the CDC and WHO start shouting numbers without properly testing individuals of course the public is going to believe it because you know that people believe everything that has a breaking news headline. <sarcasm implied on that last statement.>

You said: "Sure someone makes a dollar, but it was justified."
I dont even need to say much to to prove that this statement is absolutely rediculous: Read this article and look at the charts I have included for the 2 pharma companies who killed financially with this exagerated flu:

http://www.timesonline.co.uk/tol/news/uk/health/Swine_flu/article6737507.ece


Roche chart: If you notice that in March of last year coincidently when the swine flu was hyped, Roche was at its lowest point in 5 years. No coincidence. http://www.marketwatch.com/investing/stock/RHHB.Y/charts?countryCode=US&submitted=true&intflavor=advanced&origurl=%2Ftools%2Fquotes%2Fintchart.asp&time=9&freq=1&comp=Enter%20Symbol(s)%3A&compidx=aaaaa~0&compind=aaaaa~0&uf=7168&ma=1&maval=50&lf=1&lf2=4&lf3=0&type=2&size=1&optstyle=1013

GSK chart: Same exact result as the Roche chart! Coincidence? No way! Go ahead and change the time frame to 5 years and see what you get.
http://www.investorguide.com/stock-charts.php?ticker=GSK

I guess if you both choose to believe that the swine flu was deadly, then you probably bought into Obamas health care reform bill too. I sincerely hope everyone does proper research before coming to conclusions about how the WHO and CDC were out for our best interest during last years joke of a flu season.

TechKim - I agree with you.

I think anyone who doesn't believe that there was a real threat this time around, or that there will be real threats again in the future with mutations, is mistaken.

Is it not wonderfull we live in a world that can sometimes build against a common enemy such as a disease. Instead you look at it like a deliberate conspiracy to make a dollar. I disagree with your desired belief. It was not a sole government decison, but a belief from the medical council of the world. How each government responded was their own choice. My comment has been justified the day I wrote it.

Nope. Not true. It was not justified. The entire thing was overblown. Now you got the WHO trying to cover its own tracks. http://www.corbettreport.com/articles/20100413_who_coverup.htm
The death toll was extremely elevated and the fear mongering was off the charts. Some countries in Europe never even bought the swine flu shot(Poland for example see video below). So your statement that it was justified in an uneducated comment and if I were you, I'd delete it or supply some resources that justify your comment.

Controversial flu vaccine study finally published, but questions raised linger
Tue Apr 6, 9:39 PM
By Helen Branswell, Medical Reporter, The Canadian Press

TORONTO - A set of controversial studies that suggested getting a previous seasonal flu shot doubled a person's risk of catching pandemic H1N1 last spring has finally been published - though the mystery of whether the finding is real remains.

Provinces and territories scrambled to rethink their flu shot programs last fall when word of the then-unpublished findings spread like wildfire through Canadian research and public health communities. Most decided to delay their seasonal flu vaccine programs until distribution of pandemic vaccine was completed.

But outside of Canada, where the effect wasn't seen, scientists scratched their heads and dismissed the inexplicable and troubling findings as "the Canadian problem."

Publication of the research in a top flight journal - PLoS Medicine - may make some skeptics consider whether they should revise their thinking.

But the fact remains research elsewhere so far doesn't corroborate these findings and there isn't an easy way to explain why getting vaccinated against seasonal flu would make a person more susceptible to catching the new flu virus.

"I do think that they did the best they could with the data they had," said Dr. Mark Loeb, an infectious diseases expert at McMaster University in Hamilton who was not involved in the study and who has been a skeptic about the findings.

"The question is: OK, is it real? And the answer is: It's not clear."

The studies are presented as a single paper by a team of over 40 researchers including many of Canada's top influenza experts. The data are from four studies that draw cases from British Columbia, Alberta, Ontario and Quebec.

The message is consistent, across studies and provincial borders. It makes it appear that Canadians who got flu shots for the 2008-09 winter were somewhere between 1.4 and 2.5 times more likely to catch the pandemic virus last spring than people who had not been vaccinated against seasonal flu.

The lead author and person who first observed that unexpected finding admitted the results were "heretical."

Dr. Danuta Skowronski of the British Columbia Centre for Disease Control said for her, the story of this research was one of "finding results that you don't like and that others like even less."

"But that doesn't mean that we as scientists can turn a blind eye to results that we don't like," Skowronski, who has taken considerable heat professionally over the past year, said in an interview Tuesday.

She insisted she and her co-authors remain proponents of flu shots, saying the risk "if it's real" would no longer be an issue because next fall's flu shot will protect against the pandemic H1N1 virus.

If real, the effect appeared to relate to the small window when humans were initially exposed to the first pandemic virus to emerge in 41 years.

"We don't believe that the results we found in the spring, summer of 2009 should deter people from getting seasonal vaccine in subsequent seasons," Skowronski said.

Skowronski and her co-investigators were castigated in some circles for not releasing their data last fall so that others could study them and try to determine if people who had previous flu shots were at elevated risk.

They did, however, verbally outline the findings at length to public health officials federally and provincially in Canada as well as to the U.S. Centers for Disease Control and the World Health Organization.

Still, making public health policy during a pandemic based on data most people hadn't seen was far from ideal, said Dr. Ross Upshur, head of the University of Toronto's Joint Centre for Bioethics.

"There was a whole pile of issues on process that were less than optimal," he said, adding he believes there still needs to be discussion about when public health priorities trump the rules of scientific publication.

"Putting the imprimatur of a high impact peer review journal first is I think what we need to have the discussion about," Upshur said.

Journals generally won't publish material that has already been placed in the public domain.

Skowronski said the researchers had no choice but to hold off until publication, so that the findings could become part of the scientific record, to be explored by others.

"We thought it was our duty to see this through as scientists," she said.

Skowronski admitted one journal turned the work down - a turn of events that added to the delay in publication. Meanwhile studies of varying quality from Mexico, the U.S., Australia and Britain have failed to find the effect seen in Canada.

Skowronski now hopes other scientists - influenza immunologists especially - will mount studies to see if there was something about the body's response to the new virus that could explain this unexpected effect.

Loeb said some researchers have data sets that can be explored to try to shed more light on the issue. He has one - a prospective study of vaccinated and non-vaccinated Hutterite communities.

Dr. Ed Belongia, director of the epidemiology research centre at the Marshfield Clinic Research Institute, in Marshfield, Wis., also has data. He's looked at it - and it does not corroborate the Canadian findings.

Belongia said based on the Marshfield data, previous seasonal flu shots neither raised the risk of catching pandemic H1N1, nor offered any protection against it.

Still, he praised the Canadian work, saying the researchers evidently tried hard to find flaws in their studies that might have led to inaccurate results.

"Having read the actual paper as opposed to just hearing rumours about it, I'm impressed with the level of scrutiny they gave their data in terms of looking for potential bias and confounding. So in that sense I can't easily dismiss it," he said.

But the fact it hasn't been seen elsewhere still troubles Belongia. "I think it still falls under the rubric 'the Canadian problem' - even though we don't know what that means yet."
http://ca.news.yahoo.com/s/capress/100406/national/flu_vaccine_controversy

The swine flu is not dead, so I think those who think it was all done to hype it for a profit are just shy of reality.

Sure someone makes a dollar, but it was justified.

The 'false' pandemic: Drug firms cashed in on scare over swine flu, claims Euro health chief

The swine flu outbreak was a 'false pandemic' driven by drug companies that stood to make billions of pounds from a worldwide scare, a leading health expert has claimed.
Wolfgang Wodarg, head of health at the Council of Europe, accused the makers of flu drugs and vaccines of influencing the World Health Organisation's decision to declare a pandemic.
This led to the pharmaceutical firms ensuring 'enormous gains', while countries, including the UK, 'squandered' their meagre health budgets, with millions being vaccinated against a relatively mild disease.

A resolution proposed by Dr Wodarg calling for an investigation into the role of drug firms has been passed by the Council of Europe, the Strasbourg-based 'senate' responsible for the European Court of Human Rights.
An emergency debate on the issue will be held later this month.
Dr Wodarg's claims come as it emerged the British government is desperately trying to offload up to £1billion of swine flu vaccine, ordered at the height of the scare.

Chief Medical Officer Sir Liam Donaldson last year ordered the NHS to plan for up to 65,000 deaths
The Department of Health warned of 65,000 deaths, set up a special advice line and website, suspended normal rules so anti-flu drugs could be given out without prescription and told health and local authorities to prepare for a major pandemic.
Planners were told to get morgues ready for the sheer scale of deaths and there were warnings that the Army could be called in to prevent riots as people fought to obtain drugs.
But with fewer than 5,000 in England catching the disease last week and just 251 deaths overall, Dr Wodarg has branded the H1N1 outbreak as 'one of the greatest medical scandals of the century'.
He said: 'We have had a mild flu - and a false pandemic.'
He added the seeds of the scare were sown five years ago, when it was feared the much more lethal bird flu virus would mutate into a human form.
The 'atmosphere of panic' led to governments stockpiling the anti-flu drug Tamiflu and putting in place 'sleeping contracts' for millions of doses of vaccine
Dr Wodarg said: 'The governments have sealed contracts with vaccine producers where they secure orders in advance and take upon themselves almost all the responsibility.
'In this way the producers of vaccines are sure of enormous gains without having any financial risks.
'So they just wait, until WHO says "pandemic" and activate the contracts.'



Read more: http://www.dailymail.co.uk/news/article-1242147/The-false-pandemic-Drug-firms-cashed-scare-swine-flu-claims-Euro-health-chief.html#ixzz0gHMkkXex

NEWS SCAN: H5N1 vaccine problems, outbreaks in 2 countries
Feb 3, 2010

Indonesian scientist says H5N1 may be outwitting poultry vaccines
An Indonesian virologist says the H5N1 avian influenza virus in Indonesia may have evolved so as to make the poultry vaccines used there less effective, according to a report in the Jakarta Globe. The virologist, I Gusti Ngurah Mahardhika, said genetic differences of up to 8.7% were found when viral isolates collected at farms with vaccinated flocks in 2008 and 2009 were compared with a virus isolated from Legok, Banten, in 2003. The Legok virus is still being used by most vaccine producers in Indonesia, the story said. Mahardhika suggested that the viral mutations may explain a series of outbreaks in Indonesian flocks over the past 2 years and said he had "strong evidence" that vaccines based on the Legok virus are not effective against newer strains. Another scientist, Amin Soebandrio of the University of Indonesia, said he concurred with Mahardhika's findings and commented, "We need to see whether the changes increase the capacity of the virus to infect the human respiratory system."
Feb 2 Jakarta Globe report

Cambodia, Vietnam report H5N1 outbreaks
Cambodian authorities began culling ducks yesterday to control an H5N1 avian flu outbreak that killed more than 15,000 ducks last week in the southern province of Takeo, the Associated Press reported. Samples tested positive for the virus yesterday. Meanwhile, more than 1,000 ducks were infected with avian flu on a farm in Vietnam's central province of Quang Tri, leading to the culling of another 1,000 ducks, vaccination of 8,300, and other control measures, Viet Nam News reported today. The province's animal health officer said the ducks' owner was slow to report the outbreak, which allowed the disease to spread.
Feb 2 AP report on Cambodian outbreak
Feb 3 Viet Nam News report
http://www.cidrap.umn.edu/cidrap/content/other/news/feb0310scan.html

Did the WHO Exaggerate the H1N1 Flu Pandemic's Danger?

http://news.yahoo.com/s/time/20100126/hl_time/08599195660800;_ylt=Ap8.8z7YCg2NhbigHe.qI.YDW7oF;_ylu=X3oDMTJtaWYzdnQzBGFzc2V0A3RpbWUvMjAxMDAxMjYvMDg1OTkxOTU2NjA4MDAEcG9zAzE2BHNlYwN5bl9hcnRpY2xlX3N1bW1hcnlfbGlzdARzbGsDZGlkdGhld2hvZXhh